Jump Main Menu. Go directly to the main content

Sección de idiomas


Fin de la sección de idiomas

Access / Registration

Sección de utilidades

Fin de la sección de utilidades



Start of main content

María Vallet Regí (Universidad Complutense de Madrid) Daniel Jaque (Universidad Autónoma de Madrid) Luis Paz-Ares (Hospital Universitario 12 de Octubre de Madrid)

Nanoparticles in cancer

Life and Matter Sciences Scientific Symposium Thursday, 17 March 2022, 19:00 hours Real Academia Nacional de Farmacia. Madrid

General information:

Organized with Real Academia Nacional de Farmacia  

Venue: Real Academia Nacional de Farmacia. Calle Farmacia ,11. Madrid.

Free assistance. Please confirm in: secretaria@ranf.com – 91 531 03 07.


Honorio Carlos Bando CasadoProf. Honorario de la Facultad de Medicina de la Universidad Autónoma de Madrid y Académico correspondiente de la Real Academia Nacional de Farmacia

  • Description
  • Programme
  • Speaker/s

 Mesoporous silica can be used to produce nanotransporters that can house drugs inside.  It is necessary to chemically treat their walls, both inside and outside, to introduce antitumor drugs that destroy cancer cells, and chemically treat their surface to ensure that they do not agglomerate, that they are invisible to the immune system and that they travel to the right location, that is, that they search specifically for the place where they must act.

In addition, so that its load does not leave prematurely, smart nanogates, intelligent nanolayers or coatings of certain polymers can be placed. Using stimuli such as UV radiation, ultrasound, heat or magnetic signals, they can release their load in the right place and at the right time. These nanoparticles are true super-agents, versatile, capable of recognizing problems and providing solutions. And they can do this selectively by attacking only the exact areas where the problem exists. In this nanoparticles in cancer day, the preclinical point of view will be also discussed, as well as innovative clinical treatments in oncology.

Thursday,  17 March

19:00 h.


Antonio L. Doadrio Villarejo 
Presidente de la Real Academia Nacional de Farmacia.

José María Medina Jiménez 
Vicepresidente del Comité Científico de la Fundación Ramón Areces. Académico numerario de la Real Academia Nacional de Farmacia.



María Vallet Regí 
Catedrática de la Universidad Complutense de Madrid. Académica numeraria de la Real Academia Nacional de Farmacia.

Daniel Jaque 
Catedrático de la Universidad Autónoma de Madrid. Vicerrector de política científica de la Universidad Autónoma de Madrid.

Luis Paz-Ares 
Jefe del servicio de oncología médica del Hospital Universitario 12 de Octubre de Madrid.


  María Vallet Regí 

Professor at the Complutense University and leader of the Intelligent Biomaterials (GIBI) group, CIBER-BBN. Academic of the Royal Academies of Engineering (RAI) and National Pharmacy (RANF). Fellow of FBSE and AIMBE. She has received several national and international awards. Honoris Causa by the Universities of the Basque Country, Jaume I, Rovira and Vigil and Murcia. Pioneer in the field of mesoporous ceramic materials with application in biomedicine. Her work revealed, for the first time, the potential biomedical applications of these materials, particularly in the field of bone regeneration and controlled drug delivery systems. She is the author of more than 700 publications, 13 patents and has more than 53700 citations and an H of 110.


   Daniel Jaque

Daniel Jaque got his Ph.D. in physics from Universidad Autónoma de Madrid (Spain) in 1999. After adecade of outstanding research on laser materials and photonics, he founded the Fluorescence ImagingGroup together with Prof. J. García Solé in 2010, which has been working to develop luminescent materials nanomaterials of different kinds (quantum dots, lanthanide-doped nanoparticles, etc.) toward their application in biomedicine. Prof. Jaque was a pioneer from the dawn of luminescence thermometry; today, he is a world-renowned leader in the in vivo application of this technique.


  Luis  Paz-Ares

Dr. Paz-Ares (MD, Ph.D.) is currently Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at National Oncology Research Center, all in Madrid. He is the current President of ASEICA (Asociación Española de Investigación en Cáncer)

He graduated with a degree in Medicine from the Universidad Autónoma de Madrid, in 1986, and was trained as a resident in Medical Oncology at Hospital 12 de Octubre (1988-2001). In 1993, he completed a Ph.D. in Medicine at the Universidad Autónoma de Madrid. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, (1993– 1995), and completed a Master’s degree in Clinical Pharmacology at the University of Glasgow in 1995.

Before the current position he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007-2014)  and Vice-Director of  the IBIS (Instituto de Biomedicina de Sevilla), Head of the Pharmacology Unit and responsible for Early Clinical Studies of Thoracic and Genitourinary Tumours at the University Hospital "12 de Octubre" in Madrid (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000).

Luis Paz-Ares’s research focuses on lung cancer and new therapeutic strategies development, both at the lab and clinical sides, and has published more than 350 articles in peer review journals including New England Journal of Medicine, Lancet, Lancet Oncology, Nature Medicine, Journal of Clinical Oncology and many others (WOS H index: 82). He has served as a member of several committees, including ASCO and ESMO meeting Scientific Committees, European Organisation for Research and Treatment of Cancer Protocol Review Committee and Audit Committee, the Spanish Agency of Medicines and Medical Devices and the European Medicines Agency. He has also been the Chief Medical Officer of the AECC where he also seats at the Scientific Foundation Board. 

  • Activities related
  • Projects related
  • News related
  • Publications related

see all

End of main content